Gainers

• Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out 3 days ago.
• SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 20.01% to $11.01. The company's market cap stands at $1.8 billion.
• Bio-Techne (NASDAQ:TECH) shares rose 19.81% to $70.54. The company's market cap stands at $9.1 billion.
• Helus Pharma (NASDAQ:HELP) stock moved upwards by 18.27% to $6.02. The company's market cap stands at $253.9 million.
• Nurix Therapeutics (NASDAQ:NRIX) stock increased by 17.3% to $22.64. The market value of their outstanding shares is at $1.9 billion.
• Oramed Pharmaceuticals (NASDAQ:ORMP) shares moved upwards by 16.99% to $5.03. The company's market cap stands at $175.9 million.

Losers

• Nano X Imaging (NASDAQ:NNOX) stock fell 49.6% to $0.79 during Thursday's regular session. The market value of their outstanding shares is at $91.8 million. As per the press release, Q1 earnings came out today.
• Passage Bio (NASDAQ:PASG) stock declined by 38.27% to $3.63. The market value of their outstanding shares is at $18.8 million.
• ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 35.73% to $4.03. The company's market cap stands at $11.5 million.
• Curis (NASDAQ:CRIS) stock fell 32.6% to $0.23. The market value of their outstanding shares is at $13.2 million.
• CDT Equity (NASDAQ:CDT) stock declined by 32.12% to $0.74. The company's market cap stands at $5.2 million.
• ARS Pharmaceuticals (NASDAQ:SPRY) stock fell 26.0% to $7.8. The market value of their outstanding shares is at $1.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.